NDC product
FLULAVAL 2026/2027
NDC 19515-822 · ID Biomedical Corporation of Quebec
Key facts
| Product NDC | 19515-822 |
|---|---|
| Proprietary name | FLULAVAL |
| Nonproprietary name | influenza virus vaccine |
| Substances | INFLUENZA A VIRUS A/SWITZERLAND/6849/2025 IVR 278 (H1N1) ANTIGEN (UV, FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/MICHIGAN/105/2025 SAN 049A (H3N2) ANTIGEN (UV, FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/TOKYO/EIS13-175/2025 ANTIGEN (UV, FORMALDEHYDE INACTIVATED) |
| Dosage form | SUSPENSION |
| Route | INTRAMUSCULAR |
| Labeler | ID Biomedical Corporation of Quebec |
| Product type | VACCINE |
| Marketing category | BLA |
| Application number | BLA125163 |
| Marketing start | Jul 1, 2026 |
| Marketing end | Jun 30, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory